EasyBlog

This is some blog description about this site

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, Ph.D. as VP of CMC and Supply Chain.

Dr. Morten Sommer, Chief Scientific Officer of AntibioTx commented: ”As the company continues to expand into new areas the role of CMC becomes increasingly important for our success. We are delighted to have engaged with such a capacity as Umar and are looking very much forward working with him on the team”

Umar Hayat, Ph.D. will be the VP of CMC and Supply Chain at AntibioTx and will, in particular, be responsible for the late-stage clinical part of CMC. Dr. Hayat has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa, Anacor and Transcept Pharmaceuticals. Played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety profile for topical use.

The Ocular Irritation in vitro study evaluated the potential for causing eye damage using gold standard tests. ATx201 2%, 4% and Placebo were all classified as a non-irritant supporting the safety profile of ATx201 with regards to eye contact.

The Phototoxicity in vivo study determined the potential phototoxic effects of ATx201 Gel formulations when administered topically on the skin of hairless mice, followed by exposure to ultraviolet B, ultraviolet A and visible light.

The results provoked no cutaneous phototoxicity following topical dermal administration of the placebo or 2% or 4% ATx201. Dr. Morten Sommer, CSO of AntibioTx concluded: “The safety of ATx201 is of critical importance due to our focus on diseases that are very common in the pediatric population”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as CFO and Mads Jellingso as VP of Commercialization

Dr. Rasmus Toft-Kehler, CEO and Co-founder commented “Strengthening our management team is critical for the company’s continued development and long-term success. What is common for Morten Boesen and Mads Jellingso is that they bring important experience and expertise from globally leading institutions within their respective fields. I am excited that they have decided to join our team at AntibioTx to support the next stage of our venture”.

Morten Boesen will take on the role as Chief Financial Officer, starting from April 1, 2018. Since 2011, Mr. Boesen has worked with EQT, the leading private equity fund in the Nordics, initially as an investment manager and subsequently as an executive director in the EQT-owned global retailer, Tiger. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank, and in the finance department of Novozymes, the world leader in industrial biotechnology. Mr. Boesen holds a M.Sc. in Finance and Accounting from Copenhagen Business School.

Mads Jellingso will take on the role of Vice President of Commercialization. Mr. Jellingso joins AntibioTx from Novo Nordisk, where he most recently specialized in global market access and innovative contracting. Mr. Jellingso also has experience from the legal affairs and finance departments of Novo Nordisk, and prior to that he worked as a management consultant with McKinsey & Company and management advisor in Nordea Market. Mr. Jellingso holds a M.Sc. in Economics from University of Copenhagen.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

 

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the U.S Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) approval of AntibioTx’s ATx201 for treatment of microbiome related skin disorders.

“The FDA approval of our IND is very well-timed since we are ready to initiate studies in North America” said Dr. Lutz Wevelsiep VP of Drug Regulatory Affairs of AntibioTx” The approval to conduct studies in the US has been a key prioritization for a long time and therefore this is a fundamental milestone for AntibioTx”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, OCTOBER 26, 2017 - AntibioTx A/S has signed a 150 M DKK (20 M EUR) financing agreement with the European Investment Bank to support late-stage clinical trials for the lead candidate ATx201. ATx201 represents a new class of antibiotics with a novel mode of action and is being developed as an innovative treatment for bacterial skin infections.

The financing agreement is supported by InnovFin - a joint initiative of the European Investment Bank and the European Commission to finance innovative healthcare projects. The financial support recognizes recent progress in AntibioTx and the potential value of the platform to respond to the immense threat from antibiotic resistance posed on global public health.

The AntibioTx platform comprises both short and long-term opportunities at the intersection of microbiology and immunology. In 2017 AntibioTx successfully completed the first clinical study and is currently conducting another five clinical studies in Phase I and Phase II on lead candidates. Data from these studies are expected in 2018.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News